Tag Archives: respiratory

CVC Strategic Opportunities Sells Entire Stake in Genetic S.p.A., Strengthening the Company’s Global Position

(IN BRIEF) CVC Strategic Opportunities II has successfully exited its investment in Genetic S.p.A., a pharmaceutical CDMO specializing in Respiratory, Ophthalmic, and Oncology therapeutic products. The exit sees NB Renaissance and NB Aurora joining the Pavese family as shareholders. Under … Read the full press release

GSK Expands Respiratory Biologics Portfolio with Aiolos Bio Acquisition

(IN BRIEF) GSK plc has finalized the acquisition of Aiolos Bio, bolstering its respiratory biologics portfolio with AIO-001, a promising long-acting anti-TSLP monoclonal antibody for treating asthma. AIO-001, set to enter phase II clinical trials, targets severe asthma patients with … Read the full press release

AstraZeneca and Amgen announce US FDA Breakthrough Therapy Designation for tezepelumab in patients with severe asthma

AstraZeneca’s first Breakthrough Therapy Designation for a respiratory medicine Designation based on Phase IIb PATHWAY data that demonstrated tezepelumab significantly reduced asthma exacerbations compared to placebo in severe asthma CAMBRIDGE, 12-Sep-2018 — /EuropaWire/ — AstraZeneca and its partner Amgen Inc. (Amgen) … Read the full press release

Loughborough University to receive part of UK’s health research investment on cardiovascular, respiratory and lifestyle conditions

Leicestershire, UK, 20-Sep-2016 — /EuropaWire/ — Loughborough University is to receive a slice of the UK’s largest ever investment into health research announced today by Health Secretary Jeremy Hunt. A regional consortium featuring Loughborough University and the University of Leicester, and … Read the full press release

Accredited Symptomatic Asthma CME Launched on epgonline.org

Not for audiences in the US and Canada LONDON, 26-8-2015 — /EuropaWire/ — This week, epgonline.org, the website for healthcare professionals, welcomes the launch of a free symptomatic asthma Continuing Medical Education (CME) activity, available at epgonline.org/symptomatic-asthma/cme/. Accredited by the … Read the full press release

SAVOR-TIMI-53 cardiovascular outcomes trial of ONGLYZA® results announced by AstraZeneca and Bristol-Myers Squibb

20-6-2013 — /europawire.eu/ — AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin). In this study of adult patients with … Read the full press release